- Home
- RAPT vs CTNM Comparison
RAPT vs CTNM Comparison
Compare RAPT & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAPT
- CTNM
- Stock Information
- Founded
- RAPT 2015
- CTNM 2009
- Country
- RAPT United States
- CTNM United States
- Employees
- RAPT N/A
- CTNM N/A
- Industry
- RAPT Biotechnology: Pharmaceutical Preparations
- CTNM
- Sector
- RAPT Health Care
- CTNM
- Exchange
- RAPT Nasdaq
- CTNM Nasdaq
- Market Cap
- RAPT 117.5M
- CTNM 122.9M
- IPO Year
- RAPT 2019
- CTNM 2024
- Fundamental
- Price
- RAPT $7.35
- CTNM $4.76
- Analyst Decision
- RAPT Buy
- CTNM Strong Buy
- Analyst Count
- RAPT 5
- CTNM 4
- Target Price
- RAPT $42.00
- CTNM $22.50
- AVG Volume (30 Days)
- RAPT 120.8K
- CTNM 128.0K
- Earning Date
- RAPT 08-07-2025
- CTNM 08-12-2025
- Dividend Yield
- RAPT N/A
- CTNM N/A
- EPS Growth
- RAPT N/A
- CTNM N/A
- EPS
- RAPT N/A
- CTNM N/A
- Revenue
- RAPT N/A
- CTNM N/A
- Revenue This Year
- RAPT N/A
- CTNM N/A
- Revenue Next Year
- RAPT N/A
- CTNM N/A
- P/E Ratio
- RAPT N/A
- CTNM N/A
- Revenue Growth
- RAPT N/A
- CTNM N/A
- 52 Week Low
- RAPT $5.67
- CTNM $3.35
- 52 Week High
- RAPT $30.60
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- RAPT 43.57
- CTNM N/A
- Support Level
- RAPT $6.88
- CTNM N/A
- Resistance Level
- RAPT $8.91
- CTNM N/A
- Average True Range (ATR)
- RAPT 0.70
- CTNM 0.00
- MACD
- RAPT -0.16
- CTNM 0.00
- Stochastic Oscillator
- RAPT 11.36
- CTNM 0.00
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.